FDA approves new antibiotic for complicated urinary tract infections

The Food and Drug Administration yesterday approved an antibacterial drug to treat adults with complicated urinary tract infections, including kidney infections caused by susceptible gram-negative microorganisms who have limited or no alternative treatment options. The drug’s labeling includes a warning regarding a higher all-cause mortality rate observed in patients treated with the new drug compared to those treated with other antibiotics in a trial involving critically ill patients with multidrug-resistant gram-negative bacterial infections.